485 patents
Page 18 of 25
Utility
Medication Packaging and Dispensing System
4 Nov 20
A medication packaging and dispensing system is provided.
Lori Kim, Alexandra Breban-Lopez, Bhimaprasad Medhal, Dejan Bojicic, Guy Upchurch, John G. Finch, Lewis Sita
Filed: 16 Jul 20
Utility
Modulators of the Integrated Stress Pathway
4 Nov 20
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, SeungWon Chung, Zhaoming Xiong, Kathleen J. Murauski, Qingwei I. Zhang, Brian S. Brown, Michael J. Dart
Filed: 1 Nov 18
Utility
Modulators of the Integrated Stress Pathway
4 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Lei Shi, Kathleen J. Murauski, Xiangdong Xu, Yunsong Tong, John T. Randolph, Michael J. Dart, Hanae Benelkebir, Steven Edeson, Kathryn Starbuck
Filed: 29 Apr 20
Utility
Solvated Forms of a Bruton?s Tyrosine Kinase Inhibitor
4 Nov 20
Described herein are solvates of the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof.
Erick Goldman, Mark S. Smyth, Thierry Bonnaud, Alberto Munoz Garcia, Christopher P. Worrall
Filed: 26 Nov 19
Utility
Synthesis of a Bruton's Tyrosine Kinase Inhibitor
4 Nov 20
Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
Cyril Ben Haim, Wei Chen, Erick Goldman, Andras Horvath, Philip Pye, Mark S. Smyth, Erik J. Verner
Filed: 3 Dec 19
Utility
Methods for Treating Spinal Cord Injury and Pain
4 Nov 20
Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.
Bernhard Klaus MUELLER, Peer B. JACOBSON
Filed: 10 Dec 19
Utility
Composition and method for the diagnosis and treatment of iron-related disorders
2 Nov 20
Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Filed: 1 Nov 18
Utility
Glucocorticoid Receptor Agonist and Immunoconjugates Thereof
28 Oct 20
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, JR., John T. Randolph
Filed: 15 Apr 20
Utility
ANTI-B7-H3 Antibodies and Antibody Drug Conjugates
28 Oct 20
The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
Filed: 6 Jun 17
Utility
Methods for Treating HCV
21 Oct 20
The present invention features interferon-free therapies for the treatment of HCV.
Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Frederico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhan Zhang
Filed: 29 Aug 18
Utility
Apoptosis-inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
21 Oct 20
Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bc1-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
Filed: 8 Dec 19
Utility
Spiro-cyclic amine derivatives as S1P modulators
19 Oct 20
Axel Stoit, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Maria J. P. van Dongen, Nicolas J.-L. D. Leflemme, Adrian Hobson
Filed: 12 Nov 18
Utility
Systems and methods for tubing delivery
19 Oct 20
Adapters for a connector assembly for percutaneous tubing are provided.
Kellan William Babbs, Nolan Harrington Baird, III, Antonio Juan Belton, Sean Joel Corrigan, Charles Michael Galitz, Thomas Paul Grazier, Daniel Joseph Greene, Keith Aaron Grider, Thomas Joseph Huemann, Wayne Phillip Klingler, Michael Honsing Lau, Tomas Andrius Matusaitis
Filed: 9 Jul 15
Utility
Macrocyclic MCL-1 Inhibitors and Methods of Use
14 Oct 20
Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
Filed: 10 May 20
Utility
Process for the Preparation of (S)-2-AMINO-NON-8-ENOIC Acid
14 Oct 20
Disclosed herein is a process for preparing enantioenriched (S)-2-aminonon-8-enoic acid by amination of 2-oxonon-8-enoic acid in the presence of an enzyme and an ammonia source.
Michael J. Abrahamson, Julie J. Pruyne, Angelica B. Kielbus, John E. Lallaman, Rajarathnam E. Reddy, Sanjay R. Chemburkar
Filed: 3 Nov 19
Utility
ANTI-SEZ6 Antibody Drug Conjugates and Methods of Use
7 Oct 20
Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody dmg conjugates to treat cancer.
David LIU, Julia GAVRILYUK, Alexander SCHAMMEL
Filed: 21 Jun 20
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
7 Oct 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman ALLIAN, Thomas B. BORCHARDT, Jayanthy JAYANTH, Patrick J. MARROUM, Peter T. MAYER, Mathew M. MULHERN, Fredrik Lars Nordstrom, Ahmad Y. SHEIKH
Filed: 17 Jun 20
Utility
ANTI-PD-1 Antibodies and Their Uses
7 Oct 20
The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Daniel E.H. AFAR, Fiona A. HARDING, Josue SAMAYOA
Filed: 21 Jun 20
Utility
ANTI-CD25 Antibodies and Their Uses
30 Sep 20
The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
Filed: 10 Jun 20
Utility
Protein Tyrosine Phosphatase Inhibitors and Methods of Use Thereof
23 Sep 20
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym
Filed: 3 Jun 20